XPO1-dependent nuclear export as a target for cancer therapy

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

(2019) Michael Shafique et al.   ONCOLOGIST

LRPPRC: A Multifunctional Protein Involved in Energy Metabolism and Human Disease

(2019) Jie Cui et al.   Frontiers in Physiology

Altered nuclear export signal recognition as a driver of oncogenesis

(2019) Justin Taylor et al.   Cancer Discovery

STK 38 kinase acts as XPO 1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes

(2019) Alexandre PJ Martin et al.   EMBO REPORTS

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma

(2019) Yuanhui Liu et al.   Journal of Hematology & Oncology

Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma

(2019) Asfar S. Azmi et al.   CLINICAL CANCER RESEARCH

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

(2018) Weiguo Zhang et al.   HAEMATOLOGICA

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

(2018) Amy Y. Wang et al.   Journal of Hematology & Oncology

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer

(2018) Xiao X. Wei et al.   ONCOLOGIST

CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity

(2018) David M. Saulino et al.   Oncotarget

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

(2018) Weiguo Zhang et al.   HAEMATOLOGICA

Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.

(2018) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.

(2018) Bhavana Bhatnagar et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor

(2018) Vinod Vijay Subhash et al.   Scientific Reports

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

(2018) Nizar J. Bahlis et al.   BLOOD

XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy

(2017) Vincent Camus et al.   Journal of Hematology & Oncology

Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer

(2017) Arjun Gupta et al.   Journal of Thoracic Oncology

Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1

(2017) A Cosson et al.   LEUKEMIA

Am I ready for CRISPR? A user's guide to genetic screens

(2017) John G. Doench   NATURE REVIEWS GENETICS

An Exportin-1–dependent microRNA biogenesis pathway during human cell quiescence

(2017) Ivan Martinez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery

(2017) Laurent Volpon et al.   RNA

AACR Project GENIE: Powering Precision Medicine through an International Consortium

(2017)   Cancer Discovery

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration

(2017) Asfar S. Azmi et al.   Oncotarget

CRM1 Inhibitors for Antiviral Therapy

(2017) Cynthia Mathew et al.   Frontiers in Microbiology

HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells

(2017) Ranganayaki Muralidharan et al.   Scientific Reports

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

(2016) Ying Chen et al.   CLINICAL CANCER RESEARCH

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II  to the Nucleus

(2016) P. Ranganathan et al.   CLINICAL CANCER RESEARCH

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia

(2016) Thomas B. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

(2016) J Etchin et al.   LEUKEMIA

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

(2016) Jimi Kim et al.   NATURE

Integrated genetic and pharmacologic interrogation of rare cancers

(2016) Andrew L. Hong et al.   Nature Communications

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

(2016) Robert Nakayama et al.   Oncotarget

Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling

(2016) Hiu-Fung Yuen et al.   Oncotarget

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

(2015) Z. A. Hing et al.   BLOOD

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas

(2015) B. Culjkovic-Kraljacic et al.   BLOOD

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

(2015) Giovanni Luca Gravina et al.   BMC CANCER

Nuclear transport factors: global regulation of mitosis

(2015) Douglass J Forbes et al.   CURRENT OPINION IN CELL BIOLOGY

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

(2015) J Etchin et al.   LEUKEMIA

Control of mammalian gene expression by selective mRNA export

(2015) Vihandha O. Wickramasinghe et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185

(2015) Yoko Tabe et al.   PLoS One

A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning

(2015) Koray Kırlı et al.   eLife

RNA Export through the NPC in Eukaryotes

(2015) Masumi Okamura et al.   Genes

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer

(2015) Jiankun Gao et al.   Oncotarget

KPT-330 has antitumour activity against non-small cell lung cancer

(2014) H Sun et al.   BRITISH JOURNAL OF CANCER

KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma

(2014) Yun Zheng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics

(2014) S.-K. Low et al.   CLINICAL CANCER RESEARCH

Nucleo-cytoplasmic transport as a therapeutic target of cancer

(2014) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway

(2014) N. Saito et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

(2014) Adam L. Green et al.   NEURO-ONCOLOGY

Antitumor Effects of a Novel Chromosome Region Maintenance 1 (CRM1) Inhibitor on Non-Small Cell Lung Cancer Cells In Vitro and in Mouse Tumor Xenografts

(2014) Shuai Wang et al.   PLoS One

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

(2014) Lesley A. Mathews Griner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biological Significance of the Importin-β Family-Dependent Nucleocytoplasmic Transport Pathways

(2014) Makoto Kimura et al.   TRAFFIC

Prognostic significance of nuclear RNA export factor 3 in hepatocellular carcinoma

(2014) JIA-HAO JIANG et al.   Oncology Letters

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

(2013) C. J. Walker et al.   BLOOD

Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention

(2013) Irfana Muqbil et al.   CURRENT DRUG TARGETS

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1

(2013) Qingxiang Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

(2012) Kejie Zhang et al.   EXPERIMENTAL HEMATOLOGY

Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis

(2012) Lior Golomb et al.   MOLECULAR CELL

ValidNESs: a database of validated leucine-rich nuclear export signals

(2012) Szu-Chin Fu et al.   NUCLEIC ACIDS RESEARCH

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

(2011) K. Sakakibara et al.   BLOOD

Comprehensive Identification of Somatic Mutations in Chronic Lymphocytic Leukemia

(2011) P. Leif Bergsagel et al.   CANCER CELL

Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome

(2011) R. E. Tiedemann et al.   CANCER RESEARCH

Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways

(2011) H.-F. Yuen et al.   CLINICAL CANCER RESEARCH

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Nuclear transport and the mitotic apparatus: an evolving relationship

(2010) Richard Wozniak et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The nuclear export receptor XPO-1 supports primary miRNA processing in C. elegans and Drosophila

(2010) Ingo Büssing et al.   EMBO JOURNAL

The Nuclear Pore Complex and Nuclear Transport

(2010) S. R. Wente et al.   Cold Spring Harbor Perspectives in Biology

A fraction of Crm1 locates at centrosomes by its CRIME domain and regulates the centrosomal localization of pericentrin

(2009) Qinying Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

(2009) S. C. Mutka et al.   CANCER RESEARCH

Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP

(2009) Ivan Topisirovic et al.   EMBO JOURNAL

EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS

(2009) Aiguo Shen et al.   NEUROSURGERY

CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs

(2009) D. Castanotto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Joining the dots: Production, processing and targeting of U snRNP to nuclear bodies

(2008) Debra J. Shaw et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Localized RanGTP Accumulation Promotes Microtubule Nucleation at Kinetochores in Somatic Mammalian Cells

(2008) Liliana Torosantucci et al.   MOLECULAR BIOLOGY OF THE CELL